Loading...
NPI 1841236791 · Cambridge, MA · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Howard Ying is a ophthalmology physician provider located in Cambridge, Massachusetts. This profile covers 22 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Howard Ying |
| Address | 5 Jfk St Ste 302 |
| City | Cambridge |
| State | MA |
| ZIP | 02138 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | June 21, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.5M |
| Medicaid | $149K |
Practice is centered on retina care and intravitreal therapies: the highest Medicare revenue line items are J2777 (38.4% of Medicare revenue), J0178 (22.8%), and 67028 (8.4%), and the Top 3 Medicare codes by revenue account for 69.6% of this provider's total Medicare revenue. Those codes point to a workflow focused on high-volume anti-VEGF or related intraocular injections plus associated diagnostic and procedural support rather than broad multispecialty ophthalmology.
Revenue is highly concentrated within a small set of services for both payers: the Top 3 Medicare codes account for 69.6% of Medicare revenue and the Top 3 Medicaid codes account for 84.5% of Medicaid revenue. This concentration means a few procedure/drug lines drive most of the economics of the practice and changes in utilization or reimbursement for those codes would materially affect revenue.
The provider’s payer mix is heavily Medicare–weighted: lifetime Medicare revenue is $2.5M versus $149K in Medicaid, indicating the practice is effectively Medicare-dominated in scale. Medicaid is present but represents a small fraction of lifetime revenues, so operational and growth strategies are likely driven by Medicare patient volumes and reimbursement.
Device/drug and imaging footprint shows mixed competitive standing: 92134 is an extreme outlier for Medicare (ranks #298 of 26868 providers nationally, 99th percentile; labeled “extreme outlier, far above typical national volume”), and 92014 is also notably above typical for Medicare (ranks #1047 of 35415, 97th percentile). These high-percentile imaging and exam codes support a strong diagnostic retina service-line with unusually large retinal imaging throughput relative to national peers.
Injectable drug mix is a primary revenue driver but not uniformly dominant nationally: J2777 generates the largest single-code Medicare revenue (38.4%) yet is described as a typical, unremarkable volume relative to peers (ranks #242 of 2039 nationally, 88th percentile). Conversely, J0178 supplies a sizable share (22.8%) but sits near the median national rank (ranks #1457 of 3204, 54th percentile), indicating the practice derives substantial income from specific high-price biologics without being a top national outlier for all anti-VEGF agents.
Bevacizumab usage shows stronger relative standing on Medicare than some other injectables: J9035 appears as a smaller Medicare revenue share (3.2%) but ranks highly (ranks #42 of 1852 providers nationally, 98th percentile; noted as “notably above typical national volume”), suggesting selective use of bevacizumab at volumes that outperform most peers even if it contributes a modest share of total revenue.
Procedural throughput for intravitreal injections is significant and payer-dependent: 67028 comprises 8.4% of Medicare revenue and is described as notably above typical national volume for Medicare (ranks #300 of 4255, 93th percentile), while the same code is a large share of Medicaid revenue (28.2%) but has only modest in-state standing (ranks #37 of 59 in-state, 38th percentile). This suggests the practice performs many injections overall, but its dominance varies between the national Medicare market and the local Medicaid peer set.
The provider is long-tenured on the public record (NPI enumerated 2006-06-21 (~20 years ago)), consistent with an established, specialized retina/injection practice that has built durable Medicare volume over time. That tenure, combined with high imaging and injection volumes, indicates an experienced operation where a small set of retina-focused services drive most clinical activity and revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
22 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 33,780 | $30 | $979.6K |
| J0178 | Injection, aflibercept, 1 mg | 840 | $690 | $580.7K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,190 | $100 | $214.5K |
| J7313 | Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg | 380 | $390 | $146.3K |
| J3490 | Unclassified drugs | 60 | $1,720 | $108K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,220 | $90 | $107.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,270 | $30 | $104.7K |
| J2778 | Injection, ranibizumab, 0.1 mg | 520 | $180 | $94.6K |
| J9035 | Injection, bevacizumab, 10 mg | 1,500 | $50 | $80.9K |
| J7351 | Injection, bimatoprost, intracameral implant, 1 microgram | 290 | $160 | $46.4K |
Showing 1–10 of 22
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
22 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 40 | 90 | 790 | $690 | $826.5K |
| J2777 | 2 | 50 | 7,080 | $30 | $343.1K |
| J2778 | 18 | 30 | 560 | $180 | $200.7K |
| J7313 | 1 | 10 | 380 | $380 | $146.3K |
| 67028 | 6 | 120 | 570 | $100 | $80.7K |
| J7351 | 6 | 10 | 270 | $160 | $58.3K |
| J3490 | 11 | 20 | 60 | $380 | $49.5K |
| 92014 | 54 | 1,070 | 160 | $90 | $30.1K |
| 67042 | 4 | 30 | 20 | $1,170 | $25.7K |
| J9035 | 4 | 80 | 250 | $50 | $19.7K |
Showing 1–10 of 22
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 510 | $90 | $46.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 430 | $100 | $42.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,870 | $20 | $37.5K |
| J9035 | Injection, bevacizumab, 10 mg | 210 | $100 | $21.3K |
| 99203 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the provider… | 10 | $90 | $1.2K |
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 30 | $20 | $610 |
How this provider's Medicaid billing volume and revenue compare to other Massachusetts providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Massachusetts median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J9035 | Injection, bevacizumab, 10 mg | 16 | 30 | 210 | $690 | $668.3K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 37 | 60 | 780 | $80 | $178.3K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 259 | 660 | 250 | $60 | $122.5K |
| 99203 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the provider… | 828 | 990 | 100 | $80 | $75.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 38 | 130 | 430 | $10 | $39.3K |
| 92015 | The provider determines the process of determining if a patient's vision is less than 20/20 and by what amount so that corrective lenses or contact lenses can be prescribed and produced. | 664 | 800 | 330 | $10 | $22.7K |
Other providers in the same ZIP code as Howard Ying, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Mount Auburn Hospital | MA | General Acute Care Hospital | $0 | $28M |
| Professional Ambulance & Oxygen Svc, Inc | MA | Land Ambulance | $2.8M | $13.4M |
| Cambridge Medical Supply Inc | MA | Durable Medical Equipment & Medical Supplies | $0 | $5.6M |
| Shilpa Desai | MA | Ophthalmology Physician | $1.6M | $0 |
| Christopher Robinson | MA | Ophthalmology Physician | $1M | $0 |
| Katherine Wang | MA | Neurological Surgery Physician | $489.5K | $0 |
| Nelson Aweh | MA | Internal Medicine Physician | $425.3K | $0 |
| Kyle Pond | MA | Cardiovascular Disease Physician | $366.6K | $1.2K |
| Jeffrey Leavitt | MA | Cardiovascular Disease Physician | $356.8K | $370 |
| Charles Barsam | MA | Ophthalmology Physician | $335.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.